Bookmark

Add to MyYahoo RSS

Novartis News

News on Novartis (Ticker: NVS) continually updated from thousands of sources around the net.

3 hrs ago | Business Journal

Glaxo CEO Witty to focus on 'key franchises' instead of smaller money makers

When the asset swap between GlaxoSmithKline , Novartis and Eli Lilly goes through in the first part of next year, each company says it will generate a larger portion of its overall revenue from its key focus areas.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Novartis

8 hrs ago | The Globe and Mail

Novartis, GSK, Lilly sign multibillion-dollar deals to trade business units

Joe Jimenez, CEO of Swiss drug maker Novartis, gestures during an interview with Reuters at the company's headquarters in Basel in this March 19, 2014 file photo.

Comment?

Related Topix: Biotech, Noven Pharmaceuticals

12 hrs ago | Investor's Business Daily

Novartis, Glaxo Swap Units; Lilly Buying Animal Biz

Novartis and Glaxo rose on the stock market today , while Lilly slipped a fraction.

Comment?

Related Topix: Biotech, Medicine, Health, Influenza

16 hrs ago | Forbes.com

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital, announced a bold and unusual move by partnering with pharmaceutical company, Valeant Pharmaceuticals International plc's cancer-drug business for $14.5 billion and will sell most of its vaccine business to GSK for $7.1 ... (more)

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Forest Labs

20 hrs ago | Local Tech Wire

Novartis swaps businesses with GSK, plans to sell Holly Springs plant

Meanwhile, Novartis also plans to sell its huge vaccine production facility in Holly Springs in a separate deal.

Comment?

Related Topix: Biotech, Novartis, Healthcare Industry

Yesterday | The Huffington Post

Novartis Signs Multi-Billion Dollar Deals With GlaxoSmithKline, Lilly

Drug maker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.

Comment?

Related Topix: Biotech, GlaxoSmithKline, Medicine, Healthcare Industry

Yesterday | The Miami Herald

Novartis, GSK, Lilly in multibillion-dollar deals

Myles Chefetz does a tasting in the kitchen at Prime Fish with chef Todd Zimmer, April 14, 2014.

Comment?

Related Topix: Biotech, Restaurant Management

Mon Apr 21, 2014

GuruFocus.com

PetMed Express Inc. Is Trying Harder to Push Sales

PetMed Express Inc. is a leading nationwide pet pharmacy and Vet-VIPPS accredited, delivering prescription and non-prescription medications, and pet supplies.

Comment?

Related Topix: Biotech, Marketing

BioSpace

Clinical Trial Of Juno Therapeutics Cell Therapy Restarts

Earlier this month, a study of a much-watched cell therapy that genetically modifies patients' immune cells in order to attack tumors was stopped because the treatment may have caused the deaths of two patients.

Comment?

Related Topix: Biotech

Thu Apr 17, 2014

The Independent

Last leader of violent animal rights group jailed for six years

Debbie Vincent was part of group that falsely accused Huntingdon Life Sciences workers of being paedophiles, posted sanitary towels claimed to be infected with AIDS, and desecrated the grave of the mother of a pharmaceutical company director Note: We do not store your email address but your IP address will be logged to prevent abuse of this ... (more)

Comment?

Related Topix: Animal Rights, Prison, Activism, Biotech

Tue Apr 15, 2014

BioSpace

Novartis AG Ditches RNAi Development In Boston, Job Cuts Cited

Novartis isn't the only one hiring, others are hiring too! Check it out! Novartis is shuttering a large part of its once-ambitious RNAi research efforts in Boston, FierceBiotech has learned.

Comment?

Related Topix: Biotech

Cambridge Evening News

Stop Huntingdon Animal Cruelty (Shac) campaign against Huntingdon...

An animal rights protest group which aims to close down research firm Huntingdon Life Sciences was dubbed "quasi-terrorist" by an international pharmaceutical company seeking to protect staff against harassment.

Comment?

Related Topix: Animal Rights, Biotech

Mon Apr 14, 2014

Nucleic Acids Research

Computational modeling identifies key gene regulatory interactions...

Here, we have identified key candidate regulators of phenobarbital -mediated mouse liver tumorigenesis, a well-characterized model of non-genotoxic carcinogenesis, by applying a new computational modeling approach to a comprehensive collection of in vivo gene expression studies.

Comment?

Related Topix: Biotech, Novartis, Medicine, Healthcare Industry, Pharmacology

Sun Apr 13, 2014

Seeking Alpha

China Biotech In Review: WuXi Receives Award For cGMP...

BVCF, a China private equity growth investor specializing in healthcare and life sciences, has closed its third fund, BVCF III, L.P, with capital of $188 million .

Comment?

Related Topix: Biotech, Healthcare Technologies, Healthcare Services Group, Medicine, Apparel, Healthcare Industry, Vitamin C, Supplement

Thu Apr 10, 2014

Vision Monday

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler Retires

Novartis announced earlier this week the appointment of Jeff George as division head of Alcon , effective May 1, 2014.

Comment?

Related Topix: Biotech, Novartis, Medicine, Healthcare Industry, Alcon, Biogen Idec

Wed Apr 09, 2014

Star-Telegram.com

Novartis names new division head at Alcon Labs in Fort Worth

Jeff George, who now heads the Novartis generic drugs division, Sandoz, which has its global headquarters in Holzkirchen, Germany, will succeed Kevin Buehler, who is retiring from Alcon, a eye pharmaceutical maker, after 30 years.

Comment?

Related Topix: Biotech, Alcon, Fort Worth, TX

BioResearch Online

Novartis And MNM Provide 2 Million Anti-Malarial Drugs In Zambia

Novartis announced that two million units of its pediatric anti-malarial drug have been shipped to Zambia as part of ongoing efforts to eradicate the disease under its collaboration with Malaria No More and its campaign Power of One.

Comment?

Related Topix: Biotech, Malaria, Medicine, Health

BioSpace

Seattle's Juno Therapeutics Pauses Trial After Patient Deaths

One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient's own immune cells to destroy tumors.

Comment?

Related Topix: Biotech, University of Pennsylvania, Memorial SloanKettering Cancer Center, Medicine, Hospital Administration, Healthcare Industry

Tue Apr 08, 2014

BioSpace

FDA Grants Breakthrough Status Designation To Novartis AG' Meningitis B Vaccine

Novartis NVS +0.01% AG in Basel announced early this morning that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation - a rapid development track - for potential approval of BexseroA , their innovative vaccine against type B meningococcal meningitis.

Comment?

Related Topix: Food and Drug Administration, Biotech, Noven Pharmaceuticals

Sun Apr 06, 2014

CSRwire.com

Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia

BASEL, SWITZERLAND , Apr. 07 /CSRwire/ - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign.

Comment?

Related Topix: Biotech, Novartis, Medicine, Malaria, Health, Healthcare Industry, Internet, Science / Technology

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••